Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma.

BMC cancer - 14 Apr 2026

Wu Lige, Xie Tongji, Li Yan, Hao Xuezhi, Zhang Xin, Ying Jianming, Li Junling, Xing Puyuan

Abstract excerpt

BACKGROUND: The efficacy of immune checkpoint inhibitor plus chemotherapy (ICI-chemo) following third-generation EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma (LUAD) is variable and lacks reliable predictive biomarkers. This study investigated associations between treatment-naïve primary tumor transcriptomic profiles, tumor immune microenvironment (TIME) characteristics, and subsequent ICI-chemo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Protein Kinase Inhibitors

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41981503
DOI: 10.1186/s12885-026-16027-w
PMCID: PMC13191858

Genes

EGFR
SFTPC
DSP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma.PMID 41981503Read ↗

Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structuresSemantic proximity Read ↗

Distinct Spatial Programs of Response versus Resistance in Non-Small Cell Lung Cancer after Neoadjuvant ChemoimmunotherapySemantic proximity Read ↗

Tumor microenvironment and drug resistance in lung adenocarcinoma: molecular mechanisms, prognostic implications, and therapeutic strategiesSemantic proximity Read ↗

PSMB5-centered immunotherapy resistance signature predicts prognosis and drives CD8+ T cell exclusion in lung adenocarcinomaSemantic proximity Read ↗

A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancerSemantic proximity Read ↗

Longitudinal spatial multi-omics delineates tumor microenvironment remodeling across sequential EGFR-TKIs in EGFR-mutant NSCLCSemantic proximity Read ↗

High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

Single-cell and spatial landscapes reveal coordinated CD8+ T-cell programs defining responder-specific immune niches in NSCLCSemantic proximity Read ↗

Deciphering immune heterogeneity in lung adenocarcinoma via machine learning-based Differential Phenotype Immune Score: TPX2 as a key biomarker for immunotherapy resistance.Semantic proximity Read ↗

NFKBID Links SPP1⁺ Tumor-Associated Macrophages to CD8⁺ T-Cell Exhaustion and Immunotherapy Response in Lung AdenocarcinomaSemantic proximity Read ↗

Single-Cell Analysis Reveals Spatial Heterogeneity of Immune Cells in Lung AdenocarcinomaSemantic proximity Read ↗

Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.